Abstract:Alzheimer disease (AD), the most common form of dementia, is without an effective cure or preventive treatment. Recently, amyloid-beta protein (Abeta) has become a major therapeutic target. Many efforts are underway to either reduce the production of Abeta or enhance its clearance. In 1999, Schenk and colleagues first showed that active immunization with full-length Abeta lowered cerebral Abeta levels in transgenic mice. These findings have been confirmed and extended in various transgenic mouse models of AD using both active and passive Abeta immunization. Cognitive improvement also has been reported in association with active and passive Abeta vaccination in AD-like mouse models, even in the absence of significant reductions in cerebral Abeta loads. In 2004, the authors reported that active immunization with full-length Abeta in aged nonhuman primates, Caribbean vervets, reduced cerebral Abeta levels and gliosis. Proposed mechanisms of Abeta clearance by immunotherapy include disruption of Abeta aggregates, Abeta phagocytosis by microglia, neutralization of Abeta oligomers at the synapse, and increased efflux of Abeta from brain to blood. A phase IIa clinical trial was halted in 2002 because of the appearance of meningoencephalitis in approximately 6% of the AD patients. Although the exact cause of these adverse events is unknown, the immunogen, full-length Abeta1-42, may have been recognized as a self-antigen leading to an autoimmune response in some patients. Limited cognitive stabilization and apparent plaque clearance have been reported in subsets of patients who generated antibody titers. Currently, a passive immunization trial with a recombinant humanized monoclonal Abeta antibody is underway in humans. In the meantime, the authors are developing novel Abeta peptide immunogens for active immunization to target Abeta B cell epitope(s) and avoid Abeta-specific T-cell reactions in order to generate a safe and effective AD vaccine. The authors remain optimistic about the potential of such a vaccine for the prevention and treatment of AD.

Intramembranous Fragment of Amyloid-β: A Potential Immunogen for Alzheimer’s Disease Immunotherapy

Therapeutic Research of Intramembranous Fragment Vaccines of Amyloid-Β on APP Tg Mice

Efficacy of a Therapeutic Vaccine Using Mutated Β-Amyloid Sensitized Dendritic Cells in Alzheimer’s Mice

Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans

A Novel Aβ B-Cell Epitope Vaccine (rCV01) for Alzheimer’s Disease Improved Synaptic and Cognitive Functions in 3 × Tg-AD Mice

A Coimmunization Vaccine of Aβ42 Ameliorates Cognitive Deficits Without Brain Inflammation in an Alzheimer’s Disease Model

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid- had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

Improved Synaptic and Cognitive Function in Aged 3 × Tg-AD Mice with Reduced Amyloid-Β after Immunotherapy with a Novel Recombinant 6Aβ15-Tf Chimeric Vaccine.

Active Immunotherapy with 12-Mer Aβ1-42-like Assembly Vaccine Shows Efficacy in Aged 3×Tg-Ad Mice.

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid‐β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

Vaccines targeting the primary amino acid sequence and conformational epitope of Aβ had distinct effects on neuropathology and cognitive deficits in EAE/AD mice.

Vaccination of Alzheimer's Model Mice with Adenovirus Vector Containing Quadrivalent Foldable Aβ1–15 Reduces Aβ Burden and Behavioral Impairment Without Aβ-specific T Cell Response

Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine

Oral Administration of a Fusion Protein Between the Cholera Toxin B Subunit and the 42-Amino Acid Isoform of Amyloid-Β Peptide Produced in Silkworm Pupae Protects Against Alzheimer's Disease in Mice.

New developments of clinical trial in immunotherapy for Alzheimer's disease.

A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model

Co-immunization with DNA and Protein Mixture: A Safe and Efficacious Immunotherapeutic Strategy for Alzheimer's Disease in PDAPP Mice

Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer’s Disease Model Mice

Immunization with Aβ3-10-KLH vaccine improves cognitive function and ameliorates mitochondrial dysfunction and reduces Alzheimer’s disease-like pathology in Tg-APPswe/PSEN1dE9 mice

Strikingly Reduced Amyloid Burden And Improved Behavioral Performance In Alzheimer'S Disease Mice Immunized With Recombinant Chimeric Vaccines By Hexavalent Foldable A Beta(1-15) Fused To Toxin-Derived Carrier Proteins

New progress in active immunotherapy targeting to amyloid beta